12964_2016_129_MOESM7_ESM.xlsx (12.57 kB)
Additional file 7: Table S4. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
dataset
posted on 2016-02-24, 05:00 authored by Sebastian Halbach, Zehan Hu, Christine Gretzmeier, Julia Ellermann, Franziska Wöhrle, Jörn Dengjel, Tilman BrummerAnti-GAB2 IP of Imatinib, Axitinib and Sorafenib vs DMSO treated cells. SILAC ratios are normalized to GAB2. Only sites with localization probabilities greater 0.75 and Andromeda scores greater 40 are shown. PEP: posterior error probability. (XLSX 12 kb)
